Clinical Trial: DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Brief Summary: The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Detailed Summary:
Sponsor: Revance Therapeutics, Inc.

Current Primary Outcome: Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) [ Time Frame: 16 weeks ]

Original Primary Outcome: Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) [ Time Frame: 6 - 12 months ]

Current Secondary Outcome: Reduction in the visual analog pain score for the foot [ Time Frame: 16 weeks ]

Original Secondary Outcome: Reduction in the visual analog pain score for the foot [ Time Frame: 6 - 12 months ]

Information By: Revance Therapeutics, Inc.

Dates:
Date Received: November 22, 2016
Date Started: November 14, 2016
Date Completion: December 2017
Last Updated: April 27, 2017
Last Verified: April 2017